Stay updated on Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial

Sign up to get notified when there's something new on the Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The website has been updated from version 2.10.2 to 2.10.3.
    Difference
    0.3%
    Check dated 2024-09-04T03:20:34.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    The website has been updated from version 2.10.0 to 2.10.2, indicating new features or improvements.
    Difference
    0.3%
    Check dated 2024-08-13T21:51:03.000Z thumbnail image
  5. Check
    33 days ago
    No Change Detected
  6. Check
    47 days ago
    Change Detected
    Summary
    The website has been updated to version 2.10.0, introducing new features for viewing and comparing study record versions.
    Difference
    6%
    Check dated 2024-07-23T13:57:09.000Z thumbnail image
  7. Check
    54 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.9.7 from v2.9.6.
    Difference
    0.3%
    Check dated 2024-07-16T06:42:05.000Z thumbnail image
  8. Check
    68 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent revision in the content or details of the webpage.
    Difference
    0.3%
    Check dated 2024-07-02T13:30:53.000Z thumbnail image
  9. Check
    73 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent revision or update to the content of the webpage.
    Difference
    0.3%
    Check dated 2024-06-27T09:38:32.000Z thumbnail image

Stay in the know with updates to Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial page.